GI Biopharma Inc is a company founded by Dr. Xiaofa Qin aiming at developing treatment for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease and other illness associated dysbiosis of gut microbiota based on Dr. Qin’s finding that impaired inactivation of digestive proteases in the lower gut due to decrease in gut bacteria in modern society may have played a critical role.
Xiaofa Qin, MD, PhD, Founder & President, former associate professor of Beijing Medical University and assistant professor of University of Medicine and Dentistry of New Jersey (UMDNJ) and Rutgers University with more than a hundred of publications in medical research and served as adviser for World Health Organization (WHO) and editorial board of a dozen of scientific journals such as World Journal of Gastroenterology, World Journal of Gastrointestinal Pathophysiology World Journal of Clinical Cases, International Journal of Clinical and Medical Microbiology, Gastroenterology & Hepatology International Journal, MOJ Immunology, Journal of Microbiology and Experimentation, EC Nutrition, Toxicology Letters, Journal of Clinical Gastroenterology and Treatment, The Scientific Pages of Drug Design and Development, etc. Back to 2001, Dr. Qin found that impaired inactivation of digestive proteases as the result of decrease of gut bacteria in modern society along with improved hygiene and inhibition by dietary chemicals such as the widely used artificial sweeteners may have played causative role in inflammatory bowel disease (IBD). Since then he contact multiple national and international agencies and pharmaceutical companies advocating to conduct more research and develop some products in this regard, but failed to raise any action. In 2014, he left the academic and started GI Biopharma Inc aiming at developing some new treatment for IBD and other health problems associated with dysbiosis of gut microbiota by targeting the potential root cause.